MA52012A - Modulateurs de sting (stimulateur des gènes de l'interféron) à base de cyclopentane - Google Patents
Modulateurs de sting (stimulateur des gènes de l'interféron) à base de cyclopentaneInfo
- Publication number
- MA52012A MA52012A MA052012A MA52012A MA52012A MA 52012 A MA52012 A MA 52012A MA 052012 A MA052012 A MA 052012A MA 52012 A MA52012 A MA 52012A MA 52012 A MA52012 A MA 52012A
- Authority
- MA
- Morocco
- Prior art keywords
- cyclopentane
- interferon gene
- gene stimulator
- sting modulators
- based sting
- Prior art date
Links
- 108010050904 Interferons Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/6574—Esters of oxyacids of phosphorus
- C07F9/65744—Esters of oxyacids of phosphorus condensed with carbocyclic or heterocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/213—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862643467P | 2018-03-15 | 2018-03-15 | |
| US201862666204P | 2018-05-03 | 2018-05-03 | |
| US201862742532P | 2018-10-08 | 2018-10-08 | |
| US201962809990P | 2019-02-25 | 2019-02-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA52012A true MA52012A (fr) | 2021-01-20 |
Family
ID=66103038
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA052012A MA52012A (fr) | 2018-03-15 | 2019-03-12 | Modulateurs de sting (stimulateur des gènes de l'interféron) à base de cyclopentane |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US10538542B2 (fr) |
| EP (1) | EP3765474B1 (fr) |
| JP (1) | JP7266942B2 (fr) |
| KR (1) | KR20200131878A (fr) |
| CN (1) | CN111918871A (fr) |
| AU (1) | AU2019234043A1 (fr) |
| BR (1) | BR112020018593A2 (fr) |
| CA (1) | CA3093631C (fr) |
| CL (1) | CL2020002352A1 (fr) |
| CR (1) | CR20200382A (fr) |
| DO (1) | DOP2020000160A (fr) |
| EC (1) | ECSP20057847A (fr) |
| ES (1) | ES2923298T3 (fr) |
| IL (1) | IL277278A (fr) |
| MA (1) | MA52012A (fr) |
| MX (1) | MX2020009587A (fr) |
| NI (1) | NI202000058A (fr) |
| PE (1) | PE20210412A1 (fr) |
| PH (1) | PH12020551486A1 (fr) |
| RU (1) | RU2020130048A (fr) |
| SG (1) | SG11202008102VA (fr) |
| TW (1) | TWI741268B (fr) |
| UY (1) | UY38145A (fr) |
| WO (1) | WO2019175776A1 (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018392213B2 (en) | 2017-12-20 | 2021-03-04 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein |
| AU2018392212B9 (en) | 2017-12-20 | 2021-03-18 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein |
| TWI741268B (zh) * | 2018-03-15 | 2021-10-01 | 美商輝瑞股份有限公司 | 干擾素基因刺激劑（ｓｔｉｎｇ）的環戊烷為主體之調節劑 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TW202028179A (zh) | 2018-10-08 | 2020-08-01 | 美商普萊恩醫療公司 | 胺基酸化合物及使用方法 |
| AU2020355343B2 (en) * | 2019-09-25 | 2023-11-30 | Pfizer Inc. | Polyheterocyclic modulators of STING (stimulator of interferon genes) |
| WO2021206158A1 (fr) | 2020-04-10 | 2021-10-14 | 小野薬品工業株式会社 | Méthode de cancérothérapie |
| US11964978B2 (en) * | 2021-03-18 | 2024-04-23 | Pfizer Inc. | Modulators of STING (stimulator of interferon genes) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| CR20160564A (es) | 2014-06-04 | 2017-01-20 | Glaxosmithkline Ip Dev Ltd | Dinucleótidos cíclicos como moduladores de sting |
| GB201501462D0 (en) | 2015-01-29 | 2015-03-18 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| TWI741268B (zh) * | 2018-03-15 | 2021-10-01 | 美商輝瑞股份有限公司 | 干擾素基因刺激劑（ｓｔｉｎｇ）的環戊烷為主體之調節劑 |
-
2019
- 2019-03-11 TW TW108108048A patent/TWI741268B/zh not_active IP Right Cessation
- 2019-03-11 US US16/297,910 patent/US10538542B2/en active Active
- 2019-03-12 RU RU2020130048A patent/RU2020130048A/ru unknown
- 2019-03-12 CA CA3093631A patent/CA3093631C/fr active Active
- 2019-03-12 SG SG11202008102VA patent/SG11202008102VA/en unknown
- 2019-03-12 MA MA052012A patent/MA52012A/fr unknown
- 2019-03-12 CR CR20200382A patent/CR20200382A/es unknown
- 2019-03-12 JP JP2020548916A patent/JP7266942B2/ja active Active
- 2019-03-12 EP EP19717149.9A patent/EP3765474B1/fr active Active
- 2019-03-12 KR KR1020207029472A patent/KR20200131878A/ko not_active Withdrawn
- 2019-03-12 WO PCT/IB2019/052009 patent/WO2019175776A1/fr not_active Ceased
- 2019-03-12 MX MX2020009587A patent/MX2020009587A/es unknown
- 2019-03-12 CN CN201980019494.9A patent/CN111918871A/zh active Pending
- 2019-03-12 ES ES19717149T patent/ES2923298T3/es active Active
- 2019-03-12 PE PE2020001412A patent/PE20210412A1/es unknown
- 2019-03-12 AU AU2019234043A patent/AU2019234043A1/en not_active Abandoned
- 2019-03-12 BR BR112020018593-0A patent/BR112020018593A2/pt not_active IP Right Cessation
- 2019-03-13 UY UY38145A patent/UY38145A/es not_active Application Discontinuation
- 2019-12-04 US US16/702,738 patent/US10968242B2/en active Active
-
2020
- 2020-08-25 DO DO2020000160A patent/DOP2020000160A/es unknown
- 2020-08-28 NI NI202000058A patent/NI202000058A/es unknown
- 2020-09-10 IL IL277278A patent/IL277278A/en unknown
- 2020-09-11 CL CL2020002352A patent/CL2020002352A1/es unknown
- 2020-09-12 PH PH12020551486A patent/PH12020551486A1/en unknown
- 2020-09-15 EC ECSENADI202057847A patent/ECSP20057847A/es unknown
-
2021
- 2021-03-03 US US17/190,924 patent/US20210230196A1/en not_active Abandoned
-
2023
- 2023-07-24 US US18/225,589 patent/US20230382932A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA52012A (fr) | Modulateurs de sting (stimulateur des gènes de l'interféron) à base de cyclopentane | |
| MA52709A (fr) | Administration d'adn | |
| IL281930A (en) | Rna particles comprising polysarcosin | |
| MA54676A (fr) | Vaccins à base d'arn contre le vrs | |
| EP3775202A4 (fr) | Agents thérapeutiques à base d'acides nucléiques | |
| IL286825A (en) | Gene therapy for eye pathologies | |
| EP3735685A4 (fr) | Panneau d'affichage | |
| EP3860449A4 (fr) | Agencement d'électrodes | |
| EP3750149C0 (fr) | Panneau d'affichage | |
| EP3880235A4 (fr) | Thérapie génique de céroïdes-lipofuscinoses neuronales | |
| EP3577132A4 (fr) | Thérapie à base de virus oncolytique | |
| UA42295S (uk) | Комп'ютер | |
| EP3926701A4 (fr) | Panneau d'affichage | |
| DK3911354T5 (da) | AVV-formidlet genterapi, der genskaber otoferlin-genet | |
| EP3798719A4 (fr) | Panneau d'affichage | |
| EP3853365A4 (fr) | Modulateurs de l'expression de pnpla3 | |
| EP4051324A4 (fr) | Vecteurs de thérapie génique | |
| EP3596102A4 (fr) | Inhibiteurs peptidiques à base de structure ciblant le segment de formation de fibrilles de tau vqiink | |
| EP3735466A4 (fr) | Vecteurs d'orthopoxvirus modifiés | |
| EP3812741A4 (fr) | Appareil d'électrophorèse | |
| EP3982415A4 (fr) | Panneau d'affichage | |
| DK3737399T5 (da) | Atf5-peptidvarianter og anvendelser deraf | |
| EP3794410A4 (fr) | Affichage électrophorétique piézoélectrique | |
| EP4000238C0 (fr) | Techniques d'authentification d'appels | |
| EP4020945A4 (fr) | Terminal d'affichage |